Other languages Salarius Pharmaceuticals, Inc.

Equities

SLRX

US79400X3052

Delayed Nasdaq Other stock markets 11:26:41 2024-04-25 am EDT			5-day change	1st Jan Change
0.477 ^USD	-6.10%		-1.61%	-26.62%

Mar. 25	Wall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Data	MT
Mar. 25	Top Premarket Gainers	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Data	Mar. 25
Top Premarket Gainers	Mar. 25
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22
Salarius Pharmaceuticals, Inc. Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses	Feb. 22
Salarius Pharmaceuticals, Inc. Announces Update on Hematologic Cancer Phase 1/2 Clinical Trial Be Conducted At the University of Texas MD Anderson Cancer Center	Jan. 03
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Salarius Pharmaceuticals, Inc. Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program	Nov. 07
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Sector Update: Health Care Stocks Decline Thursday	23-08-10
Sector Update: Health Care Stocks Slightly Lower Thursday Afternoon	23-08-10
Sector Update: Health Care	23-08-10
Salarius Pharmaceuticals Cutting More Than 50% of Workforce While Reviewing Alternatives	23-08-10
Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives	23-08-07
Salarius Pharmaceuticals, Inc. FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients	23-07-12
Salaries Pharmaceuticals Closes $6 Million Private Placement	23-05-16
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma	23-05-09
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-27
Salarius Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	23-03-26
Salarius Pharmaceuticals Presents Sp-3164 Preclinical Data At the Inaugural Molecular Glue Drug Development Summit	23-01-27

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Salarius Pharmaceuticals, Inc.

Equities

SLRX

US79400X3052

Other languages

Filters